Clinical trial · Observational
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China
NCT01947309CI-TRIAL-00025464terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Business Decision
Summary
Brief summary (as posted)
The primary objective of this study is to document efficacy and safety data in a real-world setting of Chinese multiple myeloma patients who have received at least one prior therapy treated with REVLIMID (lenalidomide).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Revlimid (lenalidomide) | Drug | Lenalidomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Multiple Myeloma Patients Treated with Revlimid (lenalidomide)
- description
- Single Cohort of Multiple Myeloma Patients Treated with Revlimid
- interventionNames
- Drug: Revlimid (lenalidomide)
Primary outcomes (2)
- measure
- Progression Free Survival (PFS)
- timeFrame
- 2 years after enrollment of last patient
- description
- Assessment of PFS using IMWG Uniform Response Criteria
- measure
- Response Rates
- timeFrame
- 2 years after enrollment of last patient
- description
- Assessment of Response Rates (CR, VGPR, PR) using IMWG Uniform Response Criteria
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Must understand and voluntarily sign written informed consent At least 18 years old at the time of signing informed consent Diagnosed with Multiple Myeloma Must have received at least one prior Multiple Myeloma treatment at the time of signing informed consent Exclusion Criteria: * None
References
Publications (1)
- DERIVEDWang GM, Yang GZ, Huang ZX, Zhong YP, Jin FY, Liao AJ, Wang XM, Fu ZZ, Liu H, Li XL, Zhou JF, Zhang X, Hu Y, Meng FY, Huang XJ, Chen WM, Lu J. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma]. Zhonghua Nei Ke Za Zhi. 2017 Jul 1;56(7):500-506. doi: 10.3760/cma.j.issn.0578-1426.2017.07.006. Chinese. PMID 28693058